Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-23T15:34:38.691Z Has data issue: false hasContentIssue false
  • English
  • Français

One year audit of an Irish specialist psycho-gastroenterology hepatitis C service

Published online by Cambridge University Press:  13 June 2014

Marie Whitty ,
Siobhan Mac Hale  and
Frank Murray
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Audit
Information
Irish Journal of Psychological Medicine , Volume 28 , Issue 3 , September 2011 , pp. 153 - 155
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Onyike, CU. et al.Mania during treatment of chronic hepatitis C pegylated interferon and ribavirin. Am J Psychiat 2004; 161: 429–435.CrossRefGoogle ScholarPubMed
2.National Digestive Diseases Information Clearinghouse (NDDIC). Chronic Hepatitis C: Current Disease Management. 2008: 1–25.Google Scholar
3.Rifia, MAet al.Hepatitis C screening and treatment outcomes in patients with substance misuse/dependence disorders. Psychosomatics 2006; 47: 122–121.Google Scholar
4.Ionescu, G. Hepatitis C treatment today. Aids Community Research Initiative of America 2007; 16(4).Google Scholar
5.Loftis, JM., Hauser, P. Comanagement of depression and HCV treatment. Psychiatric Annals 2003; 33: 385–391.CrossRefGoogle Scholar
6.Bourgeois, JA., Rassaro, L, Canning, RD. Depression as co-pilot: Clinical implications of hepatitis C and interferon/ribavirin treatment. Psychiat Times 2005; April.Google Scholar
7.Dieperink, E, Willenbring, M. Neuropsychiatric symptoms with hepatitis C and interferon alpha. Am J Psychiat 2000; 157(6).CrossRefGoogle ScholarPubMed
8. European Association for the Study of the Liver (EASL) International Consensus Statement on Hepatitis C. Consensus Statement, February 1999.Google Scholar
9.Booth, JC., O'Grady, J, Neuberger, J. Clinical guidelines on the management of hepatitis C. Gut 2001; 49(1): 1–21.CrossRefGoogle ScholarPubMed
10.Pariante, CM., Landau, S, Carpinello, B. Interferon alpha-induced adverse effects in patients with a psychiatric diagnosis. NEJM 2002; 347: 148–149.CrossRefGoogle Scholar
11.Crone, CC., Geoffrey, MG, Wise, TN. Managing the neuropsychiatric side-effects of interferon-based therapy for hepatitis C. Cleveland Clin J Med 2004; 71(3).CrossRefGoogle ScholarPubMed
12.Dieperink, Eet al.A prospective study of neuropsychiatric symptoms associated with interferon alpha 2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44: 104–112.CrossRefGoogle ScholarPubMed
13.Hauser, Pet al.A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiat 2002; 7(9): 942–947.CrossRefGoogle ScholarPubMed